We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Stephen Miller - Senior Scientist, Early Discovery Biochemistry, Peptide Therapeutics

Stephen Miller

Senior Scientist, Early Discovery Biochemistry, Peptide Therapeutics

"It’s exciting to work with world class collaborators here at Genentech as we pursue challenging basic science questions and try to develop innovative treatments for patients in need."
2
Years at Genentech
3
Awards & Honors

My long-term interest in peptide research started during my graduate training in the Department of Chemistry at NYU, where I developed peptide-mimetic inhibitors of protein-protein interactions and studied alpha-helical peptide folding. I then did a postdoc in the Chemical Biology Laboratory of the US National Cancer Institute to develop peptide-based biomaterials that improve drug delivery and cellular permeability. I joined Genentech at the end of 2020 and am currently a Senior Scientist in the Department of Peptide Therapeutics (Early Discovery Biochemistry). Here, my group is interested in all aspects within the discovery, development, and delivery of next generation peptide drugs.

Featured Publication

Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions.

J. Am. Chem. Soc. 2020, 142, 19950-19955.

Miller, S.E.; Tusji, K.; Abrams, R.P.M.; Burke, T.R.; Schneider, J.P.